Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

t since most patients are diagnosed at an advanced stage," said Karsten Witt, M.D., Vice President, Clinical Development Oncology and Drug Safety, OSI Pharmaceuticals. "We are pleased to collaborate with Roche, Bayer and Onyx to explore Tarceva in hepatocellular carcinoma, a new disease area which if successful, has the potential to expand the use of Tarceva beyond its current indications in second/third-line non-small cell lung cancer and first-line pancreatic cancer."

About the Phase 3 Study

The international multicenter randomized placebo-controlled Phase 3 study is expected to enroll approximately 700 patients with advanced liver cancer. The study will examine whether Nexavar in combination with Tarceva prolongs survival as compared to Nexavar alone. The primary endpoint of the study is overall survival and the secondary endpoints are safety, time to radiographic progression, disease control rate and patient-reported outcome.

Patients will be randomized to receive either 400 mg of Nexavar twice daily and 150 mg of Tarceva once daily or 400 mg of Nexavar twice daily with matching placebo. The study will be conducted at more than 95 sites in North America, Europe and the Asia-Pacific region. For more information about enrolling in the study, please visit www.clinicaltrials.gov.

About Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults.(1,2) Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally.(3) More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing.
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... Brosix is always making changes to ... with a more efficient, effective, and secure experience. Most ... , 1. The ability to setup local servers for ... better service customers around the globe. , 2. The ... large customers that require millions of users in one ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Diane Walder, one of South Florida’s top cosmetic dermatologists ... Ultrashape that is designed to help her patients reduce unwanted ... Ultrashape has been praised by patients as being permanent, painless, ... other types of external fat reduction. , “If you can ... , According to Dr. Walder, Ultrashape works by targeting subcutaneous ...
(Date:11/28/2014)... Minnesota (PRWEB) November 28, 2014 ... of the few insurance marketing organizations in the ... income and asset protection marketplace. Secura Consultants is ... partnership with Principal Financial Group, a leading global ... multiple ownership interests. With the ownership interest comes ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... The following is being,issued by the Democratic ... Marca Bristo, former Chair of the National Council ... held a conference call today in,advance of John ... on,Disability Issues in Columbus, Ohio. There is speculation ...
... results -, LAVAL, QC, July 25 /PRNewswire-FirstCall/ - ... will host a conference call on,Friday, August 8 at ... results. Labopharm will report its second quarter 2008 financial,results ... day., To access the conference call by telephone, ...
... Impaired immune response after antiretroviral therapy may be due ... -- A new study challenges the long-held belief that ... ability to restore itself after HIV patients are treated ... percent to 90 percent of HIV-infected drug users are ...
... July 25, 2008 The American Society for ... of endoscopy in the bariatric surgery patient. The rising ... success in surgical interventions led to a marked increase ... U.S., from 13,365 in 1998 to 102,794 in 2003. ...
... of jobs created in the medical field slowed in June, pharmaceutical companies ... June than in previous months. , ... Seattle, WA (PRWEB) July 25, ... slowed in June overall, pharmaceutical companies reported a different kind of slowdown ...
... -, CORONA, Calif., July 25 Watson,Pharmaceuticals, ... pharmaceutical,company, announced today that its subsidiary has commenced ... in the 40mg,strength from its Davie, Florida manufacturing ... days of marketing exclusivity for being the,first to ...
Cached Medicine News:Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
(Date:11/28/2014)... , Nov. 28, 2014 The market for ... reach 7.9 billion dollars in 2014 according to Kalorama ... existing equipment and growing incidence of disease are driving ... X-Ray and Digital X-Ray: World Market Analysis ... X-Ray: World Market Analysis can be obtained at: ...
(Date:11/28/2014)... ATLANTA , Nov. 28, 2014 ... (Alimera), a pharmaceutical company that specializes in the ... has entered into a Securities Purchase Agreement with ... pursuant to which Alimera will issue shares of ... price of approximately $50.0 million upon the satisfaction ...
(Date:11/27/2014)... , Nov. 27, 2014  Javon Bea Mercy ... 19, faculty and staff at Janesville Craig High School ... from Mercy Health System physicians and Janesville ... Fire Departments and the Janesville ... Care Program, dedicated to providing schools and other organizations ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 2Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 3
... Tissues at Well-Tolerated ... Doses, ... data from a phase 1 dose-escalation trial of XL765, a,novel small molecule ... proliferation, survival, and,resistance to chemotherapy and radiotherapy. The trial is being carried ...
... III clinical trial --, CHICAGO, May 31 ... the presentation of updated results from,a 482 patient, ... dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone (VAD). Results ... in the VcD arm as induction therapy and ...
Cached Medicine Technology:Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 2Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 3Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 4Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: